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Abstract The dopamine β-hydroxylase (DβH) enzyme
transforms dopamine into noradrenaline. We hypothesized
that individuals with low activity DBH genotypes
(rs1611115 CT/TT) are more sensitive to the influence of can-
nabis and cocaine on cognitive impulse control and functional
connectivity in the limbic ‘reward’ circuit because they expe-
rience a drug induced hyperdopaminergic state compared to
individuals with high activity DBH genotypes (rs1611115
CC). Regular drug users (N = 122) received acute doses of
cannabis (450 μg/kg THC), cocaine HCl 300 mg and placebo.
Cognitive impulse control was assessed by means of the
Matching Familiar Figures Test (MFFT). Resting state fMRI
was measured in a subset of participants to determine func-
tional connectivity between the nucleus accumbens (NAc)
and (sub)cortical areas. The influence of cannabis and cocaine
on impulsivity and functional connectivity significantly
interacted with DBH genotype. Both drugs increased cogni-
tive impulsivity in participants with CT/TT genotypes but not
in CC participants. Both drugs also reduced functional con-
nectivity between the NAc and the limbic lobe, prefrontal
cortex, striatum and thalamus and primarily in individuals
with CT/TT genotypes. Correlational analysis indicated a sig-
nificant negative association between cognitive impulsivity
and functional connectivity in subcortical areas of the brain.
It is concluded that interference of cannabis and cocaine with
cognitive impulse control and functional corticostriatal con-
nectivity depends onDBH genotype. The present data provide
a neural substrate and behavioral mechanism by which drug
users can progress to drug seeking and may also offer a ratio-
nale for targeted pharmacotherapy in chronic drug users with
high risk DBH genotypes.
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Introduction
Reward seeking and impulsive behaviors such as addiction
have been associated with dopamine transmission in the lim-
bic ‘reward’ circuitry (Pierce and Kumaresan 2006; Volkow
et al. 2007). The latter constitutes a cortico-subcortical net-
work that receives modulatory input to the nucleus accumbens
(NAc) from ascending dopaminergic projections from the
ventral tegmental area (Alexander et al. 1986; Bonelli and
Cummings 2007; Perreault et al. 2011). The circuit broadly
consists of a reflective system located in the medial prefrontal
cortex and a reactive system located in the striatum. The reac-
tive system is sensitive to reward and generates impulses fol-
lowing dopaminergic stimulation of the NAc whereas the re-
flective system operates glutamatergic control over impulses
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generated in the striatum (Bechara 2005; Faure et al. 2010;
Kalivas and Volkow 2005). All drugs of abuse increase
dopamine transmission in the NAc (Nestler 2005) which
is essential for acute drug reward (Dagher and Robbins
2009; Kalivas and Volkow 2011; Volkow et al. 2011) and
may be very relevant for progressively shaping drug use
into drug seeking behavior (Kalivas 2009) by reducing in-
hibitory control over the reactive system (D’Amour-Horvat
and Leyton 2014).
Vulnerability to drug addiction and loss of inhibitory con-
trol may be affected by inter-individual variations in genetic
expression and tonic dopamine levels in the limbic circuit
(Koob 1998; Kreek et al. 2005; Volkow et al. 2007, 2011). It
has been posed that the relationship between tonic dopamine
and performance is non-linear and inverted-U shaped, with
both excessive as well as insufficient levels of dopamine
impairing cognitive control (Cools 2011; Cools and
D’Esposito 2011). A prime factor influencing tonic dopamine
in the brain is the enzyme dopamine beta-hydroxylase (DβH)
(Hess et al. 2009; Kreek et al. 2005; Weinshenker and
Schroeder 2007) that catalyzes the biotransformation of dopa-
mine into noradrenaline. A polymorphism in the DBH
encoding gene, the single nucleotide polymorphism rs
1611115 (−970C-T, formerly known as -1021C > T) accounts
for up to 50 % of the variance in the DβH enzyme activity
(Zabetian et al. 2001). Individuals with the high activity CC
genotype are expected to display low levels of dopamine.
Individuals with low activity genotypes (CT and TT) are ex-
pected to display high levels of dopamine and have been as-
sociated with impulsive personality styles (Hess et al. 2009).
Thus, tonic dopamine levels in the limbic circuit of drug users
and their response to drugs of abuse may vary considerably
between individuals depending on their genetic make-up at
the DBH locus.
The present study was designed to measure whether inter-
individual differences in tonic dopamine metabolism (i.e.
caused by DBH polymorphism) modulate acute effects of
cannabis and cocaine on cognitive impulse control and func-
tional connectivity between striatal and cortical parts of the
limbic reward circuit. Cognitive impulsivity was assessed by
means of the Matching Familiar Figures Test (MFFT). The
latter has previously been used to demonstrate loss of cogni-
tive impulse control in drug users (Morgan 1999; Quednow
et al. 2007). Resting state fMRI was measured to determine
functional connectivity between the regions of interest (ROI)
in the NAc and remote cortical areas (Ramaekers et al. 2013).
DBH genotype was determined in all participants. It was ex-
pected that individuals with high tonic levels of dopamine (i.e.
carriers of CT/TT genotypes) would be more sensitive to the
impairing potential of cannabis and cocaine on cognitive im-
pulse control because they would experience a drug induced
hyperdopaminergic state. Likewise, it was expected that do-
paminergic stimulation of the NAc following both drugs
would reduce functional corticostriatal connectivity
(Ramaekers et al. 2013), and more so in CT/TT individuals.
Methods
Participants
Participants were recruited at 2 study sites (i.e. Maastricht and
Nijmegen) that participated in this multicenter trial. In total,
122 regular users of cannabis and cocaine (male N = 96, fe-
male N = 26) entered the study. On average, participants had
been regular users of cannabis and cocaine for 7 yrs. (min-
max: 1–23) and 3.2 yrs. (min-max:0.5–6) respectively.
Participants reported an average (SD; min-max) use of canna-
bis and cocaine on 44.8 (26.8) and 3.7 (3.5) occasions respec-
tively during the previous 3 months. Participants also reported
the use of other substances such as MDMA (88 %), amphet-
amines (73 %), mushrooms (61 %), LSD (20 %) and a range
of miscellaneous drugs (60 %) such as nitrous oxide, MDMA
crystals, DMT and ketamine. Mean (SD) age of participants
was 22.8 (3.7) yrs. Mean (SD) trait impulsivity score as
assessed with the Barratt Impulsiveness Scale was 69.5 (9.6).
Participants were recruited through advertisements in local
newspapers, flyers distributed at targeted locations (e.g., col-
lege campuses, bars, night clubs, concerts, head shops) and by
word of mouth. Candidates received a medical examination
by the medical supervisors who determined study eligibility.
The medical supervisor checked vital signs, conducted a rest-
ing 12-lead electrocardiogram (ECG), took blood and urine
samples. Participants filled out a standard questionnaire on
medical history. Standard blood chemistry, hematology,
DBH genotyping and drug screen tests were conducted on
blood and urine samples respectively.
Inclusion criteria were: written informed consent; age 18–
40 yrs.; (regular) use of cannabis (i.e. ≥ 2 times/3 mo); cocaine
use at least 5 times in the previous year, good physical and
mental health and normal weight (BMI 18-28). Exclusion
criteria were: cocaine dependence according to DSM-IV
criteria; use of psychotropic medicinal drugs, presence or his-
tory of psychiatric or neurological disorder; pregnancy or lac-
tating; cardiovascular abnormalities; excessive alcohol use (>20
units/week) or smoking (>15 cigarettes/day), and hypertension.
This study (Dutch Trial Register, trial number NTR2127)
was conducted according to the code of ethics on human exper-
imentation as described in the declaration of Helsinki (1964),
amended in Seoul (2008). The study protocol was approved by
the Medical Ethics Committee of Maastricht University.
Design, drug dose and administration
Participants entered a double-blind, placebo-controlled, 3-
way crossover study. Treatments consisted of placebo,
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450 μg/kg THC (cannabis plant material, divided over 2 suc-
cessive doses of 300 and 150 μg/kg) and a single dose of
300 mg cocaine HCl. Cannabis was prepared from batches
that contained 11–12 % THC. Cannabis doses were tailored
to each individual subject to represent weight calibrated doses
of 300 μg/kg THC and 150 μg/kg THC and administered
using a Volcano vaporizer (Storz & Bickel Volcano ®).
Cocaine HCl and placebo were administered in an opaque
white capsule. Treatments were administered using a double
dummy technique to synchronize time of maximal drug con-
centrations (Tmax) during performance testing and resting
state fMRI. Cocaine or cocaine placebo capsules were admin-
istered at 1,25 h prior (T0) to assessment of performance in the
MFFT, whereas the first dose of cannabis (300 μg/kg THC) or
cannabis placebo was inhaled 15 (T1) min prior to MFFT. A
second dose (T2) of cannabis (150 μg/kg THC) or cannabis
placebo was administered one hour after the first dose (T1)
and 30 min prior to resting state fMRI. MFFT performance
was collected from participants in both centers. However only
participants recruited by the Maastricht center (N = 61) re-
ceived a subsequent fMRI session. Treatment conditions were
separated by a minimum wash-out period of 7 days and
counterbalanced across participants. Vital signs and blood
samples were taken after treatment administrations (T0, T1
and T2).
Procedures
Participants were familiarized with tests and procedures on a
separate training day prior to the treatment conditions.
Participants were instructed to refrain from drug use (except
for cannabis) throughout study participation. In the morning
of test days, absence of benzodiazepines, opiates, cocaine,
marijuana, MDMA and (meth)amphetamine was assessed
using urine screens and the absence of alcohol was measured
using a breathalyzer. Female participants underwent an addi-
tional pregnancy test. Participants were only allowed to pro-
ceed when test results for drug (except cannabis) and alcohol
use and pregnancy were negative. Participants that passed the
screen test received a standard breakfast, followed by baseline
measures of vital signs (blood pressure and heart rate) and a
sample of blood.
Matching familiar figures test (MFFT)
The MFFT measures cognitive impulsivity. It involves simul-
taneous presentation of a target figure centered on the left half
of the screen and an array of six alternatives on the right half of
the screen, all except one differing in one or more details from
the target figure. The participants are asked to find the item
that exactly matches the target item by pressing a keyboard
number corresponding to each of the items. If the initial selec-
tion is incorrect, this is signaled with a beep and participants
are requested to respond again. Each subject is given 2 prac-
tice trials followed by 20 test trials. Mean latency of the first
response and total number of errors, are recorded and used to
calculate two primary measures after z-transformation : i.e. an
Impulsivity score (I-score) and an Efficiency score (E-score)
(Messer and Brodzinsky 1979). The I-score is a composite
index of impulsivity and is calculated by subtracting the stan-
dardized score of the mean latency to first response from the
standardized score of the total number of errors committed
(Zerror-Zlatency). The E-score is calculated by summing the
standardized score of the mean latency to first response from
the standardized score of the total number of errors committed
(1-(Zerror + Zlatency)).
Resting state fMRI
MRI images were obtained in a 3 T head-only scanner
(Siemens® MAGNETOM Allegra). During resting state 240
EPI whole brain functional volumes were acquired (TR = 2 s,
TE = 30 ms, flip angle = 90°, matrix = 64 × 64 × 32, voxel
size = 3.5 × 3.5 × 3.5 mm). Volunteers were asked to relax
with the eyes open during resting state measurement. For an-
atomical reference, a 3D MPRAGE (magnetization-prepared
rapid gradient echo; TR = 9.7 ms, TE = 4 ms, flip angle = 12°,
matrix = 256 × 256, voxel size = 1 × 1 × 1 mm3) image data
set was acquired.
The fMRI data were preprocessed using SPM8 software
(Welcome Trust Center for Neuroimaging, London, UK).
The first 2 volumes were removed from each fMRI data set
to allow for magnetic equilibration. Preprocessing included
3D motion correction and slice time correction. Individual
anatomical data sets were normalized to standard 3-D MNI
space. Individual functional images were realigned, co-
registered and normalized to the anatomical data, and
resampled to a voxel size of 3 × 3 × 3 mm3. Spatial smoothing
was conducted with a FWHM 4 mm Gaussian kernel.
Functional connectivity
Functional connectivity data were produced with the
MATLAB toolbox DPARSFA (Chao-Gan and Yu-Feng
2010). First, linear trends of time courses were removed
followed by low band-pass filtering (0.01–0.08 Hz) of the
preprocessed data to remove ‘noise’ attributable to physiolog-
ical parameters. In addition, nuisance covariates including 6
motion parameters, the white matter signal and the CSF signal
were removed. Two spheres (radius 4 mm) were created that
were located (in MNI space) in the NAc of the left (−9, 9,-9)
and right (9, 9,-9) hemisphere (Di Martino et al. 2008).
Average time courses were obtained for each sphere separate-
ly and correlational analysis was performed voxel wise to
generate functional connectivity maps for each sphere.
Finally, the correlation coefficient map was converted into z-
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maps by Fisher’s r-to-z transform to improve normality. Drug-
induced changes in functional connectivity of the NAc have
been shown to serve as a useful marker of drug activity in in
the brain reward circuit (Ramaekers et al. 2013).
Pharmacokinetics and pharmacogenetics
Serum was used for detection of cannabinoids whereas co-
caine and metabolites were determined in plasma. The deter-
mination of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-
THC (THC-OH), 11-nor-9-carboxy-THC (THC-COOH), co-
caine (COC), benzoylecgonine (BZE) and ecgonine methyl
ester (EME) in plasma was performed in a specialized
forensic-toxicological laboratory using validated procedures
38,39. DBH genotype was analyzed after DNA isolation from
blood collected at medical screening using standard protocols.
The DBH polymorphism (rs1611115) was genotyped using
restriction fragment length polymorphism (RFLP) analysis.
PCR was performed on 50 ng genomic DNA using 0.2 μM
forward primer (5’-TGAATGTGCCCCTAAGGCTA-3’) and
0.2 μM reverse primer (5’-CACCTCTCCCTCCTG
TCCTCTCGC-3’), 0.25 mM dNTPs, 2 U Taq DNA polymer-
ase (Invitrogen, Breda, The Netherlands) in a 1× PCR optimi-
zation buffer A (30 mM Tris-HCl pH 8.5, 7.5 mM
(NH4)2SO4, 0.75 mM MgCl2). The cycling conditions were
5 min 92 °C, followed by 35 cycles of 1 min 92 °C, 1 min
59 °C, 1 min 72 °C., and a subsequent 5 min 72 °C.To purify
the PCR-products, NucleoFast96 plates (Macherey-Nagel,
Düren, Germany) were used. Restriction reaction was per-
formed in a total volume of 15 μl, containing 10 μl purified
PCR-product, 5 U HhaI, 1× NEBuffer 4 and 1× BSA.
Digestion was performed at 37 °C for 16 h, which resulted
in two fragments of 200 bp and 24 bp for the C allele, the T
variant remained uncut (224 bp).
Statistics
A total of 122 participants entered the study. DBH geno-
type data was missing in 6 participants and MFFT
datasets of another 6 participants were incomplete, due
to technical failures. Consequently, 110 participants with
complete datasets entered the statistical analyses of MFFT
data. For analysis, individuals with low activity DBH ge-
notypes, i.e. CT (N = 33) and TT (N = 4), were pooled
(CT/TT) and compared to CC homozygotes (N = 73). A
total of 61 participants (the Maastricht sample) participat-
ed in resting state measures. fMRI datasets were incom-
plete for 22 participants due to technical failures or due to
excessive movement during drug conditions, rendering 39
participants with complete fMRI datasets. DBH genotype
was missing in 4 of those participants, which rendered 35
participants with complete datasets to test for Drug x
DBH interactions on functional connectivity.
Effects on impulse control tasks from oral THC and co-
caine HCl in dosages similar to those proposed for this study
have achieved statistical significance in within subject designs
employing 20 or less participants (Fillmore et al. 2006;
Ramaekers et al. 2006a; Ramaekers and Kuypers 2006).
Assuming an omnibus p < 0.05 and power = 0.8, we estimated
that the present study employing 122 subjects would enable
detection of performance differences between drug treatments
with an effect size of 0.3 (i.e., a signal change of .3 times the
standard deviation) in within subject comparisons. In addition,
we estimated that between DBH group comparisons of geno-
types would enable detection of performance differences with
an effect size of .7 and .4 for sizes of N = 30 and N = 60
respectively. Straightforward power analysis for imaging data
is less feasible. Because fMRI data analysis consists of a very
large number of non-independent multiple comparisons, a
proper power analysis with correction for multiple compari-
sons requires computer simulation. In addition, statistical
power is not the same (i.e., homogenous) over the brain, but
varies across brain regions (Petersson et al. 1999). A common
approach in the functional neuroimaging community is to es-
timate the number of subjects from previous empirical expe-
rience in the field, particularly when pilot data are lacking and
analyses include the whole brain ormultiple regions of interest
(Mumford 2012). Previous resting state fMRI studies have
employed 15–20 subjects for showing significant drug effects
(Honey et al. 2003; Kelly et al. 2009; Ramaekers et al. 2013;
Schrantee et al. 2015). Based on these experiences we expect-
ed no problem to demonstrate drug effects on fMRI measures
in 60 participants and that sample sizes of subgroups DBH
genotypes (N = 15–30) would be sufficient for demonstrating
between group differences.
MFFT measures were analyzed with SPSS 21.0 using a
GLM univariate analysis of variance (ANOVA) with Drug
(3 levels; placebo, cannabis and cocaine) as within subject
factor and DBH genotype (2 levels; CC and CT/TT) as be-
tween group factor. The model tested for main effects of Drug,
DBH genotype and their interaction. Significant main effects
were subsequently followed by drug-placebo contrasts to es-
tablish the separate effects of cannabis (2 within subject levels;
placebo and cannabis) and cocaine (2 within subject levels;
placebo and cocaine) and their interaction with DBHgenotype
(2 between group levels; CC and CT/TT).
Functional connectivity data (i.e. correlation coefficient
maps for each individual in each treatment condition) were
analysed in 2 GLM models of ANOVA in SPM8. In the first
GLM, complete datasets of 39 participants were analysed
using ANOVA with Drug (3 levels) as within subject factor.
The GLM model established the effects of cannabis and co-
caine separately by means of drug-placebo contrasts. DBH
genotyping was only available for 35 participants (CC geno-
type N = 22; CT/TT genotype N = 13) that were included in
GLM 1. Therefore a 2nd GLM was conducted that included
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35 participants for which both resting state and DBH data sets
were complete. These data were entered in an ANOVA with
Drug (3 levels) as within subject factor and DBH genotype (2
levels) as between group factor. From this model, main effects
of DBH genotype and its interaction with cannabis and co-
caine treatment were identified. The statistical threshold was
set at p < .05 FWE cluster corrected (cluster size >50).
Finally, voxel wise correlation analysis between FC data
and MFFT composite measures of Impulsivity and Efficiency
were conducted.
Results
Matching familiar figures test (MFFT)
All MFFT measures demonstrated a significant main effect of
the factor Drug. The interaction factor Drug x DBH genotype
also reached significance for all MFFT measures except
Efficiency. There was no main effect of DBH genotype in
any of the MFFT parameters.
Separate contrasts revealed that cocaine significantly in-
creased Impulsivity (F1,108 = 8,9; p = .004) and decreased
Response latency (F1,108 = 7.0; p = .009) overall. Cannabis
significantly reduced Efficiency (F1,108 = 27.6; p = .000), in-
creased Errors (F1,108 = 20.5; p = .000) and Response latency
(F1,108 = 5.2; p = .024) overall. The influence of cocaine on
MFFT performance significantly interacted with DBH geno-
type. Cocaine increased Impulsivity (F1,108 = 9.0; p = .003)
and Errors (F1,108 = 4.0; p = .049) and decreased Response
latency (F1,108 = 6.1; p = .015) in CT/TT individuals but not in
CC individuals. The influence of cannabis on MFFT perfor-
mance also significantly interacted with DBH genotype.
Cannabis increased Impulsivity (F1,108 = 6.2; p = .014) and
Errors (F1,108 = 5.5; p = .021) in CT/TT but not in CC indi-
viduals. Mean (se) performance in the MFFT in each drug
condition averaged over DBH genotypes and for individuals
with CC and CT/TT genotypes separately are shown in Fig. 1.
Functional connectivity
GLM contrast showed that overall, cannabis as well as co-
caine significantly reduced functional connectivity with NAc
seeds in both hemispheres, relative to placebo. Reductions in
functional connectivity were prominent in the cingulate gyrus
as well as in broad areas of the frontal, temporal, parietal and
occipital lobes. GLM contrasts did not reveal any positive
changes (drug > placebo) in functional connectivity.
Figure 2 shows the decrements in functional connectivity for
each drug-placebo contrast across DBH genotypes and for
individuals with CC and CT/TT genotypes separately.
GLM analyses of interaction between DBH genotype and
cannabis and cocaine revealed that reductions in functional
connectivity in striatum, thalamus, cingulate gyrus and fron-
tal, parietal and temporal lobes were most prominent in indi-
viduals with CT/TT genotypes. There was no main effect of
DBH genotype. Figure 3 shows significant interactions be-
tween drug-placebo contrast and DBH genotype for NAc
seeds in both hemispheres. A summary of brain areas showing
significant decrements in functional connectivity with the
NAc is given in Table 1. Reported are data obtained from
the NAc seed in the right hemisphere. These were generally
identical to those obtained for the NAc seed in the left hemi-
sphere (not shown).
Correlation of MFFTand functional connectivity data
Voxel wise correlation analysis revealed significant (negative)
correlations between Impulsivity scores and functional connec-
tivity in the striatum (MNI peak: -2, 2, 4) and thalamus (MNI
peaks: -2, -28, 10; 4,-20, 16) across genotypes, indicating that
Impulsivity levels increased when functional connectivity de-
creased. Correlations between functional connectivity and the
MFFT measure of Impulsivity in the striatum and the thalamus
Fig. 1 Mean (se) performance in the MFFT during drug and placebo
challenges averaged over DBH groups and for carriers of CC and CT/TT
genotypes separately (CAN = cannabis, COC = cocaine, PLA = placebo);
* = p < 0.05 (drug-placebo contrasts across genotypes); + = p < 0.05 (drug x
DBH genotype interaction)
1258 Brain Imaging and Behavior (2016) 10:1254–1263
were generally significant in all treatment conditions as shown
in Fig. 4. Overall, correlation between Impulsivity and function-
al connectivity were comparable for CC individuals (r = −.38
and −.33) and CT/TT individuals (r = −.27 and −.35) across
treatments in the 2 identified areas. Efficiency was not signifi-
cantly correlated with functional connectivity data.
Control measures
One-way ANOVA revealed that DBH groups did not differ in
cannabis and cocaine use over the previous 3 months.
Likewise, age, gender distribution and trait impulsivity (as
assessed with the Barratt Impulsiveness Scale) did not differ
between groups. Finally, THC and cocaine concentrations did
also not significantly differ between DBH groups. Mean con-
centrations of THC, cocaine and their main metabolites aver-
aged over groups are given in Table 2.
Discussion
MFFT data indicated that both cannabis and cocaine signifi-
cantly increased cognitive impulsivity in individuals with CT/
TT genotypes but not in CC homozygotes. The former
changed from a reflective decision style during placebo (i.e.
low impulsivity scores) to an impulsive decision style during
drug intoxication (i.e. higher impulsivity scores). This is illus-
trated by the finding that CT/TT participants responded more
rapidly at the cost of making more errors during cocaine and
made more errors despite prolonged decision times during
cannabis intoxication. CC homozygotes revealed relatively
high impulsivity scores during placebo that did not alter dur-
ing drug intoxication. Single doses of cannabis (Ramaekers
et al. 2006a) and cocaine (vanWel et al. 2013) have previously
been reported to increase motor and cognitive impulsivity,
particularly at higher doses (Fillmore et al. 2006) or higher
drug concentrations (Ramaekers et al. 2009). Based on the
present study it now appears that changes in impulsive deci-
sion making may be limited to individuals with CT/TT geno-
types and that their (default) reflective operation mode is more
prone to the disinhibiting effect of cannabis and cocaine.
Both drugs also decreased synchronicity between BOLD
responses in the NAc and other areas of the brain. In particu-
lar, cannabis and cocaine decreased functional connectivity
between the NAc and the limbic lobe (i.e. anterior cingulate),
medial prefrontal cortex, striatum and thalamus. Reductions in
functional connectivity were most prominent in individuals
with CT/TT genotypes. These decrements may be largely
Fig. 2 NAc related functional
connectivity decrements
following cannabis and cocaine in
the left and right hemisphere,
relative to placebo. Shown are
thresholded (t = 2.34) Z-score
maps of functional connectivity
(a) averaged over DBH
genotypes and (b) for individuals
with CC and CT/TT genotypes
separately (CAN = cannabis,
COC = cocaine; left = left; planes
are made at MNI seed position)
Fig. 3 NAc related functional connectivity decrements as a function of
cannabis x DBH and cocaine x DBH interactions in the left (LH) and right
hemisphere (RH), (CAN = cannabis, COC = cocaine; left = left; planes
are made at MNI seed position)
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related to the moderating effects of cannabis and cocaine on
GABAergic projections to output nuclei within the basal gan-
glia. Both drugs elevate dopamine levels in the NAc (Bossong
et al. 2009; Kalivas and Duffy 1990; Weiss et al. 1992) which
in turn increases inhibitory GABAergic neurotransmission to
the ventral pallidum through D1 receptor stimulation in the
direct pathway. Inhibitory output to the ventral pallidum leads
to reduction of GABAergic, inhibitory tone to the dorsomedial
Table 1 Summary of brain areas showing decrements in functional connectivity with the NAc (right hemisphere) following cannabis and cocaine and
their interaction with DBH genotype
Overall BA Voxel x y z FWE
Cannabis vs placebo
Left, frontal, limbic lobe, (anterior) cingulate gyrus 6,9, 24, 32 24,785 −36 −4 42 .000
Left frontal lobe, Right frontal lobe, Left thalamus 47 373 −18 −32 −8 .002
Left, temporal lobe, cerebellum 36 374 −48 −36 −26 .000
Left, temporal lobe, occipital lobe 37,38 1213 −32 −48 −16 .000
Right, temporal lobe, middle temporal gyrus 21 741 66 −8 −10 .000
Right. Occipital lobe, cerebellum 18 313 30 −78 −8 .003
Right, insula, claustrum 13 430 43 4 1 .003
Cocaine vs placebo
Left, parietal lobe, temporal lobe 5,7,22, 39, 40 30,270 −38 −44 66 .000
Left, occipital lobe, Right cerebellum 18 903 −20 −64 −8 .000
Right, left frontal, limbic lobe, (anterior) cingulate gyrus 9, 24, 32 1021 40 26 36 .000
Cannabis x DBH
Left, frontal and parietal lobe 3,6 474 −36 −4 42 .000
Left, parietal lobe 5,7,40 397 −28 −50 62 .000
Right, temporal and parietal lobe 19,39 512 32 −74 30 .000
Right, limbic lobe, (anterior) cingulate gyrus 24,32 12,000 4 −4 33 .000
Cocaine x DBH
Left and right frontal lobe; Right, limbic lobe, (anterior) cingulate gyrus 8,9, 24, 32 10,580 −8 40 53 .000
Left, parietal lobe 40 19,330 −58 −40 38 .000
Left, temporal lobe, putamen, globus pallidus, thalamus 21,22 22,670 −21 −6 11 .000
Right, parietal and temporal lobe 22,40 13,920 50 −40 34 .000
Right, parietal, temporal, occipital lobe 19,39 10,090 26 −66 −28 .000
Right, cerebellum, Limbic lobe, parahippocampal gyrus 28,34,36 13,260 26 −66 −28 .000
Fig. 4 Significant correlations in the striatum and the thalamus between functional connectivity and theMFFTmeasure of impulsivity in each treatment
condition (CAN = cannabis, COC = cocaine, PLA = placebo), across DBH genotypes
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nucleus of the thalamus, which, in turn, projects to the limbic
areas of the cerebral cortex (Kalivas and Volkow 2005;
Nakanishi et al. 2014; Pierce and Kumaresan 2006). In addi-
tion, dopamine also turns down the inhibitory, indirect striatal
pathway from the NAc to the thalamus via D2 receptor acti-
vation (Nakanishi et al. 2014). The net effect of dopaminergic
stimulation of D1 and D2 receptors in the NAc is therefore
‘disinhibition’ and increased thalamic feedback on pleasure
and reward to the cerebral cortex. Loss of functional connec-
tivity may reflect elevation of striatal ‘bottom-up’ impulses at
the cost of ‘reflective’ top-down control from frontal parts in
the limbic circuit. Indeed, correlational analyses confirm a
strong association between cognitive impulsivity and func-
tional connectivity in the subcortical areas (i.e. striatum, thal-
amus) of the brain. Impulsivity increased with lower function-
al connectivity in these areas, and this association was stron-
gest in the drug conditions. This corresponds with the notion
of striatal overdrive due to increased dopaminergic stimula-
tion of the NAc and the subsequent ‘disinhibition’ of the thal-
amus which acts as the major relay between the reactive and
reflective part of the reward system.
Drug induced disinhibition of corticostriatal circuits and
subsequent loss of cognitive control may also provide an im-
portant mechanism by which drug users can progress to drug
seeking. In the present study, loss of functional corticostriatal
connectivity was particularly prominent in the (supracallosal)
anterior cingulate and medial prefrontal cortex. These areas
are implicated in detection of salient or erroneous events and
the signaling of top down reorientation and implementation of
attention (Beckmann et al. 2009; Sutherland et al. 2012).
Reduced brain activity in these areas has been associated with
comprised abilities to exert control over strong prepotent
urges in cocaine users (Hester and Garavan 2004).
Reductions in functional corticostriatal connectivity have also
been reported in chronic users of cocaine (Camchong et al.
2014; Gu et al. 2010; Tomasi et al. 2010) and cannabis
(Fischer et al. 2014) during abstinence. This suggests that a
drug induced imbalance in the corticostriatal circuitry can en-
dure during abstinence in chronic users and lead to long last-
ing disinhibition.
Several potential limitations of the current study should be
addressed. First, sample size in the current study, appears
low to study genetic polymorphism. It has been argued that
sample size should be well above a hundred participants or
more to reliable assess genetic –environment (e.g. drug) inter-
actions (Duncan and Keller 2011). The implication of a low
sample size is that true genotype × drug effects may go unde-
tected or that rate of false discoveries progressively increases
with the number of candidate genes that are being screened for
drug interactions (Duncan and Keller 2011). This argument is
particularly true for association studies that randomly screen
for a multitude of candidate gene-drug interactions. However,
the present experimental study instead tested a single hypoth-
esis about a single candidate gene (i.e. DBH) to exclude risk of
chance capitalization and type 1 statistical errors. In such a
scenario, sample size considerations are essentially not differ-
ent from those in any other study making between group com-
parisons. The current study was well powered to demonstrate
drug x DBH interactions in the MFFT. Sample size for resting
state data was lower, but still within a sufficient range to pick
up drug effects as demonstrated in previous studies (Honey
et al. 2003; Kelly et al. 2009; Ramaekers et al. 2013;
Schrantee et al. 2015). Moreover, pearson r correlations be-
tween functional connectivity and MFFT demonstrated a sig-
nificant association between these 2 datasets, with coefficients
varying between r = −30 and r = −50 indicating medium to
large effect sizes. We therefore believe that the current DBH x
drug interaction on functional connectivity is a true finding
that is in support of the same interaction that we observed in
the cognitive impulsivity data set in a much larger sample size.
Second, several study participants tested positive for THC
at baseline prior to drug and placebo administration. However,
mean baseline THC concentration was very low and below the
threshold (i.e. < 2 ng/mL) above which performance impair-
ment at the group level becomes apparent (Ramaekers et al.
2006b). Moreover, THC concentrations did not differ between
DBH groups at baseline and during treatments. Therefore dif-
ferential cannabis effects on MFFT and functional connectiv-
ity observed between DBH groups cannot be explained by
differential THC concentration but must be caused by a factor
that affects sensitivity to THC, in this case DBH genotype.
Cannabis and cocaine are also well known to affect cardio-
vascular variables. Cannabis decreases blood pressure shortly
after smoking and increases heart rate (Ramaekers et al. 2009)
whereas cocaine causes increments in both of these parame-
ters during intoxication (Fillmore et al. 2002). In the current
study we did not measure heart rate and blood pressure during
resting state to control for cardiovascular influences on the
Table 2 Mean (sd) concentrations of THC, cocaine and their main metabolites at baseline (T0) and prior to MFFT (T1) and resting state fMRI (T2)
THC
[ng/ml]
THC-OH
[ng/ml]
THC-COOH
[ng/ml]
Cocaine
[mg/L]
BZE
[mg/L]
EME
[mg/L]
T0 1.57 (4.14) 0.62 (1.72) 20.91 (37.68) 0.00 (0.0) 0.00 (0.00) 0.00 (0.00)
T1 73.81 (63.09) 6.86 (4.32) 38.69 (33.38) 0.25 (0.19) 0.49 (0.27) 0.14 (0.11)
T2 46.00 (34.19) 5.79 (3.51) 42.27 (36.03) 0.31 (0.18) 1.12 (0.37) 0.26 (0.10)
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BOLD response. Instead we removed ‘noise’ attributable to
such physiological parameters by low band-pass filtering
(0.01–0.08 Hz) of the preprocessed data. Moreover, the po-
tential of drug induced cardiovascular influences on the
BOLD response is similar across DBH groups and therefore
cannot explain drug x DBH interactions as observed in the
present study.
The present study included an unequal distribution of
males and females. In total, 122 regular users of cannabis
and cocaine entered the study of which 26 were females.
The gender distribution did not differ between DBH groups.
Sample sizes of males and females did not allow for further
gender specific analyses, particularly of the resting state
dataset. Further studies however may wish to address the issue
of gender specificity in terms of drug x DBH interactions since
several studies have demonstrated gender specific responses
to reward related decision processing (Diekhof et al. 2012;
Lighthall et al. 2012).
The present study demonstrated that individual responses
to cannabis and cocaine challenges vary with DBH genotype.
Heterogeneity in response to drug challenges may also have
important clinical implications as these might be useful for
developing personalized, targeted treatment in subgroups of
drug dependent patients. Increased sensitivity to dopaminer-
gic challenges make individuals with CT/TT genotypes more
prone to downregulation and depletion of the dopaminergic
system as has been observed in chronic drug users (Bough et
al. 2014). Preliminary data suggests that replenishment of do-
pamine through pharmacotherapy would therefore be more
successful in patients with CT/TT genotypes as compared to
patients with CC genotypes (Liu et al. 2014).
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